Bolt Biotherapeutics, Inc. (BOLT) Reports Q2 Loss, Tops Revenue Estimates

Bolt Biotherapeutics, Inc. (BOLT) came out with a quarterly loss of $4.46 per share versus the Zacks Consensus Estimate of a loss of $6.4. This compares to a loss of $11.2 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +30.31%. A quarter ago, it was expected that this company would post a loss of $6.8 per share when it actually produced a loss of $5.8, delivering a surprise of +14.71%.Over the last four quarters, the company ...